期刊文献+

双控释型格列齐特缓释胶囊的研制 被引量:2

暂未订购
导出
摘要 格列齐特属磺酰脲类降糖药,用于治疗2型糖尿病因其疗效好,不良反应较少等已处于用药主导地位。格列齐特人体半衰期为12h,为维持有效血药浓度须每日给药两次以上,患者可能漏服,且可发生低血糖不良反应。普通片需2~3次/d,剂量80~320mg/d,且其用药后体内药物浓度波动大,患者需长期服用,顺应性差。
出处 《华夏医学》 CAS 2013年第1期153-155,共3页 Acta Medicinae Sinica
  • 相关文献

参考文献6

二级参考文献21

  • 1刘宝林.格列齐特缓释片的制备与释放度测定[J].江苏药学与临床研究,2004,12(3):27-28. 被引量:3
  • 2卢骏,吴涛,胡建平,潘卫三.格列齐特缓释片的制备及体外释放度[J].中国医药工业杂志,2004,35(7):410-412. 被引量:17
  • 3吴涓,王洪泉,黄蓓琳,张晴峰.不同厂家格列齐特片溶出度考察[J].中国药房,2005,16(4):300-302. 被引量:8
  • 4国家药典委员会编.中华人民共和国药典,2000年版,二部[S],附录XIX D,缓释、控释制剂指导原则[M].北京:化学工业出版社,.附录,200.
  • 5国家药典委员会编.中华人民共和国药典,2000年版,二部[S],格列齐特原料及片质量标准[M].北京:化学工业出版社,.702.
  • 6Aggarwal S, Rani M,Srivastava AK,et al.. Studies on gliclazide β-hydroxypropylmethylcellulose complexes and its tablets[J]. Pharmaceutical and Pharmacological Letters,2001, 11(2) ,78-82.
  • 7[1]Palmer K J, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulindependent diabetes mellitus [J]. Drugs, 1993, 46 (1): 92-125.
  • 8[5]Palmer KJ,Brogden RN.Gliclazide.An update of its pharmacological properties and therapeutic efficacy in non-insulindependent diabetes mellitus[J].Drugs,1993,46(1):92.
  • 9Yang SH, Dou KF, Song WJ. Prevalence of diabetes among men and wom- en in China [J]. N Engl J Med,2010,362(25):2425-2426.
  • 10ATC/DDD Index 2008. WHO Collaborating Centre for Drug statistics Methodology [Z]. Olso Norwegian,2008.

共引文献62

同被引文献25

  • 1陈晓昱,张志荣,任科,龚涛.辣椒碱-羟丙基-β-环糊精包合物制备鉴定及热力学稳定性研究[J].中国中药杂志,2009,34(4):394-397. 被引量:12
  • 2陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2013:651.
  • 3Hussain T, Saeed T, Mmntaz A M ,et al. Efict of two hydrophobic pol- ymers on the release of gliclazide fl'om their matrix tablets[ J ]. Aeta Pol Pharm ,2013,70(4 ) :749 - 757.
  • 4Nguyen C, Chrislensen J M, Ayres J W. Compression ot coated drug beads for sustained release taMer of glipizide: formulation, and dissolu- tion[ J]. tharm Dev Teehno1,2014 ,19 ( 1 ) : 10 - 20.
  • 5He W, Li Y, Zhang R,et al. Gastro - floating bilayer tablets for the sustained release of metformin and immediate release ff pioglitazone: Preparation and in vitro/in vivo evaluation [ J ] Int J Pharos, 2014,476 (1 -2) :223 -231.
  • 6Ige P P, Gattani S G. Design and ir vitro and in vivo characterization of mucoadhesive matrix pellets of mettbmfin hydrochloride for oral con- trolled release : a technical note [ J ]. Arch Pharm Res,2012,35 ( 3 ) : 487 - 498.
  • 7Tiwari R, Gupta A, Joshi M,et al. Bilayer Tablet Formulation of Met- formin HCI and Acarbose: A Novel Approaeh To Control Diabetes[J]. PDA J Phann Sci Technol,2014,68(2) :138 - 152.
  • 8Koh N, Sakamoto S, Chino F. Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet [ J ]. To- hoku J Exp Meal,2008,216(3 ) :249 -257.
  • 9Desai N S, Nagarsenker M S. Design and evaluation of self - nanoemul- sifying pellets of repaglinide[ J ]. AAPS Phm'm Sci Tech, 2013,14 (3) : 994 - 1003.
  • 10Qin c, He W, Zhu C. Controlled release of metformin hydrochloride and repaglinide from sandwiehed osmotic pump tablet [ J ]. lnt J Pharm, 2014,466( 1 -2) :276 -285.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部